

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. 21251
First Inventor or Application Identifier Balkrishen Bhat, et al.
Title NUCLEOSIDE DERIVATIVES AS INHIBITORS OF
RNA-DEPENDENT RNA VIRAL POLYMERASE
Express Mail Label No. EV321982466US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO: Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

1. ☒ Fee Transmittal Form
(Submit an original, and a duplicate for fee processing)
2. ☒ Specification [Total Pages 46]
3. ☐ Drawing(s) (35 USC 113) [Total Sheets]
4. Oath or Declaration
 - a. ☐ Newly executed (original or copy)
 - b. ☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 14 completed)
 - i. ☐ **DELETION OF INVENTOR(S)**

Signed statement attached deleting
inventor(s) named in the prior
application, see 37 CFR 1.63(d)(2)
and 1.33 (b).
5. ☐ Application Data Sheet. See 37 CFR 1.76
6. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
 - a. ☐ Computer Readable Form (CRF)
 - b. ☐ Specification Sequence Listing on:
 - i. ☐ CD-ROM or CD-R (2 copies); or
 - ii. ☐ paper
 - c. ☐ Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

7. ☐ Assignment papers (cover sheet & document(s))
8. ☐ 37 CFR 3.73(b) Statement (when there is an assignee) ☐ Power of Attorney
9. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
10. ☐ Preliminary Amendment
11. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
12. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
13. ☒ Other: Unsigned Declaration

14. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No. ____ / ____
Prior application information: Examiner _____ Group/Art Unit: _____


For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.

15. CORRESPONDENCE ADDRESS

☒ Customer Number

Customer No. 000210

NAME	Philippe L. Durette					
ADDRESS	Merck & Co., Inc., P. O. Box 2000 - Patent Dept., RY60-30					
CITY	Rahway	STATE	NJ	ZIP CODE	07065-0907	
COUNTRY	USA	TELEPHONE	732-594-4568	FAX	732-594-4720	

Name	Philippe L. Durette	Registration No. (Attorney/Agent)	35,125
Signature		Date	10/28/2003

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT October 28, 2003

EXPRESS MAIL NO. EV321982466US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

MAILED BY Lore Schepers

DATE 10/28/03

16638 U.S. PTO
102803

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Deposit Acct. 13-2755
MERCK & CO., INC.
Our Case Docket No. 21251

Sir:

Transmitted herewith for filing under 37 C.F.R. §1.53(b) is the patent application of Inventor(s):
Balkrishen Bhat, Steven S. Carroll, Anne B. Eldrup, Malcolm MacCoss, David B. Olsen, Daniel R. McMasters, Jie Xia


For: NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE

For	Number Filed	Number Extra	Rate	Basic Fee \$770
Total Claims	15 - 20 =	0 X	\$18	= \$0
Independent Claims	3 - 3 =	0 X	\$86	= \$0
Multiple Dependent Claims*			\$290	=
* Add this fee if application contains any multiple dependent claims, regardless of number.		TOTAL FILING FEE →		\$770

Please charge my Deposit Account No. 13-2755 in the amount of \$ 770. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Account No. 13-2755. Duplicate copy of this sheet is enclosed.

☐ Under the provisions of 37 C.F.R. §1.53, this application is being filed without the declaration of each inventor.

Respectfully,



By: Philippe L. Durette

Attorney For Applicant(s)

Reg. No. 35,125

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732) 594-4568

Date: October 28, 2003

EXPRESS MAIL CERTIFICATE	
DATE OF DEPOSIT	<u>October 28, 2003</u>
EXPRESS MAIL NO.	<u>EV321982466US</u>
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.	
MAILED BY	<u>Don Schepers</u> DATE <u>10/28/03</u>

IN DUPLICATE